Can-Fite Announces New Findings on Namodenoson's Dual Anti-Cancer and Liver Protective Effects
Portfolio Pulse from Benzinga Newsdesk
Can-Fite BioPharma Ltd. (NYSE:CANF) announced breakthrough findings on Namodenoson's dual anti-cancer and liver protective effects, mediated by the signalling protein adiponectin. These findings will be presented at the IDDST-2024 conference in Shanghai. Namodenoson is currently in Phase III and Phase IIb clinical trials for advanced liver cancer and MASH, respectively.
June 24, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Can-Fite BioPharma Ltd. (NYSE:CANF) announced new findings on Namodenoson's dual anti-cancer and liver protective effects, mediated by adiponectin. The data will be presented at the IDDST-2024 conference. Namodenoson is in Phase III and Phase IIb trials for advanced liver cancer and MASH.
The announcement of breakthrough findings and the upcoming presentation at a major conference are likely to generate positive sentiment around Can-Fite BioPharma. The ongoing clinical trials for Namodenoson in advanced liver cancer and MASH further add to the potential positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100